AYAL Capital Advisors Ltd Has $11.25 Million Stake in Orthofix Medical Inc. $OFIX

AYAL Capital Advisors Ltd lessened its position in Orthofix Medical Inc. (NASDAQ:OFIX) by 10.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 742,372 shares of the medical device company’s stock after selling 87,528 shares during the period. Orthofix Medical comprises about 3.9% of AYAL Capital Advisors Ltd’s portfolio, making the stock its 3rd largest holding. AYAL Capital Advisors Ltd’s holdings in Orthofix Medical were worth $11,254,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. Rubric Capital Management LP lifted its stake in shares of Orthofix Medical by 0.7% during the 2nd quarter. Rubric Capital Management LP now owns 3,721,715 shares of the medical device company’s stock worth $41,497,000 after buying an additional 26,769 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its stake in shares of Orthofix Medical by 34.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock worth $37,248,000 after buying an additional 858,900 shares during the last quarter. Juniper Investment Company LLC lifted its stake in shares of Orthofix Medical by 15.3% during the 3rd quarter. Juniper Investment Company LLC now owns 2,847,055 shares of the medical device company’s stock worth $41,681,000 after buying an additional 377,729 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Orthofix Medical by 86.6% during the 3rd quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock worth $21,605,000 after buying an additional 684,850 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Orthofix Medical by 6.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,142,545 shares of the medical device company’s stock worth $16,726,000 after buying an additional 68,596 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on OFIX. Stifel Nicolaus dropped their price objective on shares of Orthofix Medical from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Barrington Research dropped their price objective on shares of Orthofix Medical from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Friday, May 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research note on Tuesday, April 21st. Canaccord Genuity Group dropped their price objective on shares of Orthofix Medical from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 21st. Finally, TD Cowen reiterated a “hold” rating on shares of Orthofix Medical in a research note on Thursday, May 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Orthofix Medical currently has a consensus rating of “Hold” and an average price target of $15.50.

Orthofix Medical Trading Down 1.9%

OFIX opened at $9.23 on Thursday. Orthofix Medical Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $16.99. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.87 and a quick ratio of 1.76. The firm has a market capitalization of $373.08 million, a price-to-earnings ratio of -6.11 and a beta of 0.71. The company’s 50 day moving average price is $11.22 and its two-hundred day moving average price is $12.88.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings data on Tuesday, May 5th. The medical device company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.16. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. The company had revenue of $196.71 million for the quarter, compared to analyst estimates of $196.40 million. As a group, research analysts predict that Orthofix Medical Inc. will post -1.48 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Engine Capital Management, Lp bought 112,950 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were acquired at an average cost of $11.99 per share, with a total value of $1,354,270.50. Following the completion of the purchase, the insider directly owned 3,783,131 shares in the company, valued at $45,359,740.69. The trade was a 3.08% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jorge Andres Cedron sold 3,743 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $12.82, for a total transaction of $47,985.26. Following the transaction, the insider owned 59,006 shares in the company, valued at approximately $756,456.92. The trade was a 5.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have purchased a total of 189,896 shares of company stock valued at $2,293,970 over the last ninety days. 2.70% of the stock is owned by corporate insiders.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.